肥厚型心肌病患者COVID-19结局与持续症状:与既往心脏磁共振表型的关联
基于国际HCM注册登记中1704例有CMR表型的参与者,通过患者报告问卷评估COVID-19感染及结局。767例报告感染者中4%需住院、19%报告≥3个月恢复不良,疲劳(67%)和呼吸困难(33%)常见;校正后基线CMR特征(肥厚、LGE、ECV)与住院或恢复不良无关联。
要点
- HCM患者COVID-19后持续症状负担重,疲劳和呼吸困难常见。
- 基线CMR表型(肥厚、纤维化、ECV)未与住院或恢复不良相关。
- 女性与较年轻年龄与持续症状相关。
核心结论
- 在该大型HCM队列中,COVID-19与显著的持续症状负担相关,但既往CMR表型与不良结局无关联。
- 基线结构病变严重程度可能无法识别COVID-19后并发症高风险患者。
研究设计与样本
- 国际HCM注册登记中1704例有既往CMR表型的参与者,使用患者报告问卷评估COVID-19感染及结局。
- 采用多变量logistic回归评估基线CMR特征与住院或恢复不良(≥3个月)的关联。
主要发现
- 767例报告COVID-19感染,平均年龄49±11岁,4%需住院,19%报告≥3个月恢复不良,发生2例(0.26%)非心脏死亡。
- 持续症状常见,尤其疲劳(67%)和呼吸困难(33%)。
- 校正后,肥厚、纤维化(晚期钆增强)和细胞外容积等不良CMR特征与住院或恢复不良无关联。
- 女性性别和较年轻年龄与持续症状相关。
临床怎么用
- 对HCM患者COVID-19后应关注持续症状(尤其疲劳、呼吸困难)的评估与管理。
- 不应仅依据基线CMR表型严重程度来判断COVID-19后并发症风险。
局限性
- 结局为患者自报。
- 事件率有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of COVID-19 in hypertrophic cardiomyopathy (HCM), particularly in the post-vaccine era, remains incompletely understood. We evaluated whether pre-existing cardiovascular magnetic resonance (CMR) phenotypes are associated with COVID-19 outcomes and recovery. METHODS: In 1704 participants from the international HCM Registry with prior CMR phenotyping, COVID-19 infection and outcomes were assessed using patient-reported questionnaires. Associations between baseline CMR features and hospitalisation or impaired recovery (≥3 months) were evaluated using multivariable logistic regression. RESULTS: Among 767 participants with reported COVID-19 infection (mean age 49±11 years), 4% required hospitalisation, 19% reported impaired recovery at ≥3 months and 2 (0.26%) non-cardiac deaths occurred. Persistent symptoms were common particularly fatigue (67%) and dyspnoea (33%). After adjustment, adverse CMR features, including hypertrophy, fibrosis (late gadolinium enhancement) and extracellular volume, were not associated with hospitalisation or impaired recovery. Female sex and younger age were associated with persistent symptoms. CONCLUSIONS: In this large HCM cohort, COVID-19 was associated with a substantial burden of persistent symptoms, but pre-existing CMR phenotype was not associated with adverse outcomes. These findings suggest that baseline structural disease severity may not identify patients at higher risk of post-COVID-19 complications, although results should be interpreted in the context of self-reported outcomes and limited event rates.
引用
- Singhal A, Appleby E, Agnel O, et al. COVID-19 outcomes and persistent symptoms in patients with hypertrophic cardiomyopathy: association with pre-existing cardiovascular magnetic resonance phenotype. Heart. 2026. PMID: 42209210. doi:10.1136/heartjnl-2025-327169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。